Merck: Molnupiravir Covid-19 Pill Effective Against Omicron in Lab Tests
January 28 2022 - 7:42AM
Dow Jones News
By Colin Kellaher
Merck & Co. on Friday said its Covid-19 pill developed with
partner Ridgeback Biotherapeutics was effective against the Omicron
variant in laboratory tests.
The Kenilworth, N.J., drugmaker said data from six preclinical
studies show the antiviral drug, known as molnupiravir, was active
against the fast-spreading Omicron variant in vitro.
The U.S. Food and Drug Administration in late December
authorized doctors to prescribe molnupiravir to adults at high risk
of severe Covid-19 shortly after they develop mild-to-moderate
symptoms as part of efforts to keep newly infected patients out of
hospitals.
Pfizer Inc. earlier this month said its Covid-19 pill, Paxlovid,
was also effective against the Omicron variant in laboratory
tests.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 28, 2022 07:27 ET (12:27 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024